Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890317 | 0.89 | PARP10 (0.35) | PRMT5WDR77HSP90AA1PDE10APARP10 | |
| SCHEMBL10328266 | 0.85 | HSP90AA1 (0.36) | PRMT5WDR77HSP90AA1PARP10PARP11 | |
| SCHEMBL6893626 | 0.79 | PDGFRB (0.38) | PDE10APARP10PARP11PIK3CAMTOR | |
| SCHEMBL7881257 | 0.77 | PIK3CA (0.35) | HSP90AA1PIK3CAMTORHDAC1EGFR | |
| SCHEMBL16104617 | 0.77 | HSP90AA1 (0.35) | HSP90AA1PDE10APARP10PARP11PIK3CA | |
| SCHEMBL2686645 | 0.76 | PIK3CA (0.36) | HSP90AA1PIK3CAMTORHDAC1EGFR | |
| SCHEMBL6892192 | 0.76 | PIK3CA (0.38) | HSP90AA1PARP10PARP11PIK3CAMTOR | |
| SCHEMBL6891750 | 0.76 | EGFR (0.36) | PDE10APIK3CAHTR3AHDAC1EGFR | |
| SCHEMBL10238738 | 0.75 | AKR1C3 (0.36) | HSP90AA1PIK3CAMTOREGFRFGFR2 | |
| SCHEMBL6893608 | 0.75 | MAP4K4 (0.38) | PIK3CAMTORHDAC1EGFRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | PRMT5 1170/4885WDR77 469/4885HSP90AA1 2279/4885 |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | PRMT5 2065/4885WDR77 1105/4885HSP90AA1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.